ISPOR BIOSIMILARS SPECIAL INTEREST GROUP AND ISPOR CENTRAL AND EASTERN EUROPE CONSORTIUM- BIOSIMILARS- AN OPPORTUNITY FOR COUNTRIES WITH RESTRICTED RESOURCES TO IMPROVE PATIENT ACCESS?
Author(s)
Moderator: Vera Pataki, MD, MBA, Chair of CEE Network, Medicines for Europe, Brussels, Belgium
Speakers: Andras Inotai, PharmD, PhD, DrHabil, Associate Professor, Semmelweis University, Budapest, Hungary; Evelien Moorkens, MSc, PhD Researcher, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; Iga Lipska, MD, PhD, The Plenipotentiary of the Fund President for Hospital based HTA, National Health Fund, Warsaw, Poland; Dalia M Dawoud, MSc, PhD, Scientific Adviser, Science Policy and Research, National Institute for Health and Care Excellence (NICE), London, LON, UK
Presentation Documents
PURPOSE: To present an overview of and discuss the goals, barriers and facilitators of biosimilar adoption in countries with limited resources, from HTA and policy perspectives. DESCRIPTION: Value propositions of biosimilars are often approached from a perspective of price erosion, but they can also generate health gain. Utilising biosimilars in different decision settings necessitates scientifically rigorous yet flexible value assessment methods. Sustainable policies are also required to translate value propositions of biosimilars to real-world cost savings or health gain. Discussions will include: Dr. Inotai - current challenges facing biosimilars’ uptake from a CEE perspective; Ms. Moorkens - existing European biosimilar policies; Dr. Lipska - CEE HTA/Payer perspective and challenges in pricing negotiations on biosimilars; Dr. Dawoud - how the outputs of the SIG can provide guidance for biosimilars’ HTA and policy decision-making. Live poll and interactive discussions during the presentations and open discussion at the end will facilitate audience participation.
Conference/Value in Health Info
2019-11, ISPOR Europe 2019, Copenhagen, Denmark